Current practice in the clinical use of hematopoietic growth factors following chemo-/ radiotherapy in gynecological malignancies;DERZEITIGER STAND DER KLINISCHEN ANWENDUNG VON HAMOPOETISCHEN WACHSTUMSFAKTOREN NACH CHEMO-/STRAHLENTHERAPIE IN DER GYNAKOLOGIE

Zentralblatt fur Gynakologie

Volumn 119, Issue 12, 1997, Pages 585-596

  Karthaus, M ^a   Ganser, A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Breast cancer; Hematopoietic growth factors; High dose chemotherapy; Ovarian cancer

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; COLONY STIMULATING FACTOR 1; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; INTERLEUKIN 3; MELPHALAN; PACLITAXEL; RECOMBINANT COLONY STIMULATING FACTOR 1; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT THROMBOPOIETIN; STEEL FACTOR; THIOTEPA; THROMBOPOIETIN; VINCRISTINE;

BONE MARROW SUPPRESSION; BREAST CANCER; CELL ISOLATION; CHEMOTHERAPY; HUMAN; OVARY CARCINOMA; RADIOTHERAPY; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GENITAL NEOPLASMS, FEMALE; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RADIOTHERAPY, ADJUVANT; RECOMBINANT PROTEINS;

EID: 0031472221     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Advani R, Chao NJ, Horning SJ et al.: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 116 (1992) 183-189
2. Ayash LJ, Elias A, Wheeler C, Antman K: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: A feasibility study. J Clin Onc 12 (1994) 37-44
3. Basser R, Clarke K, Fox R et al.: Randomized, double-blind, placebo-controlled Phase I Trial of pegylated megacaryocyte growth and development factor (PEG-rHuMGDF) administred to patients with advanced cancer before and after chemotherapy - early results. Blood 86 (1995) Suppl. 1, 257a abstract 1014
4. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with haematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13 (1995) 2483-2489
5. Benedetti-Panici P, Greggi S, Scambia G et al.: High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Ann Med 27 (1995) 133-138
6. Biesma B, Willemse PHB, Mulder NH et al: Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 80 (1993) 1141-1148
7. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304 (1981) 10-15
8. Bonadonna G, Valgussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate and Fluorouracil in node-positive breast cancer. N Engl J Med 332 (1995) 901-906
9. Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, Kanz L: Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Onc 10 (1992) 1452-1459
10. Brugger W, Bross K, Frisch J, Dern P, Weber B, Mertelsmann R, Kanz L: Mobilisation of peripheral blood progenitor cells by sequential administration of interleukin-3 and graunolcyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 79 (1992) 1193-1200
11. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 333 (1995) 283-287
12. Brugger W, Mocklin W, Heimfeld S et al.: Ex vivo expansion of enriched peripheral CD 34+ progenitor cells by stem cell factor IL-1β,IL-6, IL-3, interferon-y, and erythropoietin. Blood 84 (1994) 380-383
13. Bunn PA, Crowley J, Kelly K et al.: Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospektive phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13 (1995) 1632-1641
14. Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, Testa N, Thatcher N: Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small- cell lung cancer. J Clin Oncol 13 (1995) 1623-1631
15. Cazzola M, Messinger D, Battistel V et al.: Recombinant human erythrpoietin in the anemia assocciated with multiple myeloma or non Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 86 (1995) 4446-4453
16. Crawford J, Ozer H, Stoller et al. : Reduction by G-CSF of fever and neutropenia induced by chemotherapy in patients with small-cell cancer. N Engl J Med 325 (1991) 164-170
17. Curtis BM, Williams DE, Broxmeyer HE et al.: Enhanced haematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein. Proc Nat Acad Sci USA 88 (1991) 5809-5813
18. de Vries EGE, Biesma B, Willemse PHB et al: A double-blind placebo controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 51 (1991) 116-122
19. Fushiki M, Abe M: Randomized double-blind controlled study of rhG-CSF in patients with neutropenia induced by radiation therapy. Proc Am Soc Clin Oncol 111 (1992) 410(a)
20. Ganser A, Lindemann A, Seipelt G et al.: Effect of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76 (1990) 666-676
21. Ganser A, Lindemann A, Seipelt G et al.: Sequential in vivo treatment with two recombinant hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase 1 study. Blood 79 (1992) 2583-2591
22. Gebbia V, Testa A, Valenza R: A prospective evaluation of the activity of human granulocyte colony-stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. Chemother 5 (1993) 186-190
23. Gerhartz HH, Engelhard M, Meusers P et al.: Randomized, double-blind, placebo-controlled, Phase III study of recombinant human GM-CSF as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 82 (1993) 2329-2339
24. Gianni AM, Siena S, Bregni M et al.: Growth factor supported high dose sequential adjuvant chemotherapy in breast cancer with > 10 positive nodes. Proc. ASCO 1995
25. Gorin NC, Coiffier B, Hayat M et al.: Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non Hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood 80 (1992) 1149-1157
26. Groopmann JE, Molina JM, Scadden DT: Hematopoietic growth factors. Biological and clinical applications. N Engl J Med 321 (1991) 1449-1459
27. Gulati SC, Bennett CL: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease. Ann Intern Med 116 (1992) 177-182
28. Hamm JT, Schiller JH, Oken MM et al.: Granulocyte-macrophage colony-stimulating factor (GM.CSF) in small cell carcinoma of the lung (SCCL): preliminary analysis of a randomized controlled trail. Proc Am Soc Clin Oncol 10 (1991) 255 (abstract)
29. Henry DH, Abels RI: Recombinant human erythropoietin in the treatment of cancer and cancer-related anemia: results of double blind and open label follow-up studies. Semin Oncol 21 (1994) Suppl. 3, 21-28
30. Henry DH, Abels RI: Benefits of epoetin alfa in anemic cancer patients receiving chemotherapy. J Clin Oncol 13 (1995) 2473-2474
31. Kaye SB, Lewis CR, Paul J et al.: Randomized study of two doses of cisplatin with cyclophosphamide in epithelian ovarian cancer. Lancet 340 (1992) 329-333
32. Kaushansky K: Thrombopoietin, the primary regulator of platelet production. Blood 86 (1995) 419-431
33. Kotake T, Miki T, Akaza H et al.: Effect of granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer. Cancer Chemother Pharmacol 27 (1991) 253-257
34. Krantz SB: Erythropoetin. Blood 77 (1991) 419-434
35. Lieschke GJ, Burgess AW: Drug therapy: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327 (1992) 28-35, 99-106
36. Link H, Boogaerts MA, Carella AM et al.: A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 80 (1992) 2188-2195
37. Ludwig H, Fritz E, Leitgeb C et al.: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84 (1994) 1056-1063
38. Maher DW, Lieschke GJ, Green M et. al.: Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 121 (1994) 492-501
39. Mayordomo JI, Rivera F, Diaz-Puente M et al.: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 87 (1995) 803-808
40. McGuire WP, Hoskins WJ, Brady MF et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 334 (1996) 1-6
41. Mc Niece IK, Langley KE, Zsebo KM: Recombinant human stem cell factor synergies with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 19 (1992) 226-231
42. Momin F, Kraut M, Lattin P, Valdivieso M: Thrombocytopenia in patients receiving chemoradiotherapy and G-CSF for locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 11 (1992) 294 (a)
43. Moore MAS: Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 78 (1991) 1-19
44. Mulder POM, Willemse PHB, Aalders JG et al.: High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Cancer Clin Oncol 25 (1998) 645-649
45. Nicols C, Bajorin D, Schmoll HJ et al.: VIP chemotherapy with/without GM-CSF for poor risk, relapsed or refractory germ cell tumors (GCT): preliminary analysis of a randomized controlled trial. Pro Am Soc Clin Oncol 10 (1992) 167 (a)
46. Nemunaitis J, Rabinowe SN, Singer J et al.: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324 (1991) 1773-1778
47. Olencki T, Budd GT, Murphy S et al.: Phase IA/IB trial of rhIL-6 in patients with refractory malignancy rhematologic and immunologic effects. Blood 80 (1992) Suppl 1, 89a
48. Ozer H, Miller LL, Anderson JR et al.: American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol 12 (1994) 2471-2508
49. Ozer H: American Society of Clinical Oncology guidelines for the clinical use of hematopoietic colony-stimulating factors. Current Opinion in Hematology 3 (1996) 3-10
50. Paul SR, Bennett F, Calvetti JA et al.: Molecular cloning of a cDNA encoding interleukin-11, a stromal cell derived lymphopoietic and hematopoietic cytokine. Proc Nat Acad Sci USA 87 (1990) 7512-7516
51. Peters WP, Shpall EJ, Jones RB, Ross M: High-dose combination cyclophposphamide, cisplatin, and carmustine with bone marrow support as initial treatment for metastatic breast cancer.: Three-six year follow up. Proc Amer Soc Clin Oncol 9 (1990) 10
52. Peters WP, Ross M, Vredenburgh JJ et al.: High -dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11 (1993) 1132-1143
53. Peters W: Five year follow-up of high dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving > 10 axillary lymph nodes. Proc Amer Soc Clin Oncol 15 (1995) 933a
54. Pettengell R, Gurney H, Radfford JA et al.: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non Hodgkin's lymphoma: a randomized controlled trial. Blood 80 (1992) 1430-1436
55. Postmus PE, Gietema JA, Damsma O, Biesma B, Limburg PC, Vellenga E, de Vries EGE: Effects of recombinant human interleukin-3 patients with relapsed small-cell lung cancer treated with chemotherapy: a dose finding study. J Clin Oncol 10 (1992) 1131-1140
56. Trillet-Lenoir V, Green J, Manegold C et al.: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29 (1993) 319-324
57. Schmitz N, Linch DC, Dreger P et al.: Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 347 (1996) 353-357
58. Shea TC, Mason JR, Storniolo AM et al.: Sequential cycles of high-dose carboplatin administration with recombinant human granulocyte-makrophage colony-stimulating factor and repeated infusions of autologous peripheral blood progenitor cells: a novel and effective method for delivering multiple courses of dose intensive therapy. J Clin Oncol 10 (1992) 464-473
59. Sheridan WP, Begley CG, Juttner CA et al.: Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339 (1992) 640-644
60. Shpall EJ, Stemmer SM, Bearmann SI et al.: High dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer. In: Cancer of the ovary. Eds.: Markman, Hoskins. New York: Williams and Wilkins 1993, 327-338
61. Stiff P, Bayer R, Camarda M et al.: A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelian ovarian cancer. Gynecol Oncol 57 (1995) 275-278
62. Vahdat L, Antman KH: Dose-intensive therapy in breast cancer. High-Dose Cancer Therapy (1995) 802-823
63. Vadhan-Raj S, Papadopoulos N, Burgess A et al: PIXY 321 (GM-CSF/IL-3 fusion protein) reduces chemotherapy induced multilineage myelosuppression in patients with sarcoma. Blood 80 (1992) Suppl. I, 249a
64. Weich NS, Tullai J, Guido E et al.: Interleukin-3/erythropoietin fusion protein: in vitro effects on hematopoietic cells. Exp Hematol 21 (1993) 647-655